Skip to Content

MEI Pharma Inc MEIP

Morningstar Rating
$2.89 +0.08 (2.85%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MEIP is trading at a 54% premium.
Price
$2.84
Fair Value
$7.48
Uncertainty
Extreme
1-Star Price
$96.63
5-Star Price
$6.44
Economic Moat
Dyy
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MEIP is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.81
Day Range
$2.822.90
52-Week Range
$2.737.87
Bid/Ask
$2.75 / $2.89
Market Cap
$19.26 Mil
Volume/Avg
8,270 / 16,689

Key Statistics

Price/Earnings (Normalized)
0.76
Price/Sales
0.29
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
46

Valuation

Metric
MEIP
Price/Earnings (Normalized)
0.76
Price/Book Value
0.38
Price/Sales
0.29
Price/Cash Flow
0.64
Price/Earnings
MEIP

Financial Strength

Metric
MEIP
Quick Ratio
5.88
Current Ratio
6.17
Interest Coverage
Quick Ratio
MEIP

Profitability

Metric
MEIP
Return on Assets (Normalized)
27.54%
Return on Equity (Normalized)
55.56%
Return on Invested Capital (Normalized)
39.86%
Return on Assets
MEIP
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
VvmhrjjwqYtz$598.1 Bil
Vertex Pharmaceuticals Inc
VRTX
CrpbnmzlyHzsbgj$126.0 Bil
Regeneron Pharmaceuticals Inc
REGN
XlhrjwqyJgpvst$119.6 Bil
Moderna Inc
MRNA
SjkttvxlVrf$47.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
GktpgdzShlvjz$30.4 Bil
argenx SE ADR
ARGX
BwtqsjnkmSfwh$27.4 Bil
BioNTech SE ADR
BNTX
KxtpbbsgqMmls$20.8 Bil
Biomarin Pharmaceutical Inc
BMRN
MddqjtcqPcycqr$16.1 Bil
United Therapeutics Corp
UTHR
NfxdkjcVpzd$14.7 Bil
Incyte Corp
INCY
MkpfbqbyLytjqw$12.9 Bil

Sponsor Center